Tag: PT866

Phase 1 patient dosing of PT886 for advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas is initiated by Phanes Therapeutics.

First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and pancreatic adenocarcinomas, according to Phanes Therapeutics, Inc. (Phanes), an…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram